WO2006136963A3 - Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract - Google Patents

Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract Download PDF

Info

Publication number
WO2006136963A3
WO2006136963A3 PCT/IB2006/002631 IB2006002631W WO2006136963A3 WO 2006136963 A3 WO2006136963 A3 WO 2006136963A3 IB 2006002631 W IB2006002631 W IB 2006002631W WO 2006136963 A3 WO2006136963 A3 WO 2006136963A3
Authority
WO
WIPO (PCT)
Prior art keywords
site
respiratory tract
inflammatory conditions
conditions affecting
airway administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002631
Other languages
French (fr)
Other versions
WO2006136963A2 (en
Inventor
Lars Otto Uttenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drugrecure AS
Original Assignee
Drugrecure AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure AS filed Critical Drugrecure AS
Priority to EP06795540A priority Critical patent/EP1898945B1/en
Priority to US11/993,264 priority patent/US20100279925A1/en
Priority to DK06795540.1T priority patent/DK1898945T3/en
Publication of WO2006136963A2 publication Critical patent/WO2006136963A2/en
Publication of WO2006136963A3 publication Critical patent/WO2006136963A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of natural anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of site-inactivated FVIIa or biologically active derivatives thereof .
PCT/IB2006/002631 2005-06-24 2006-06-23 Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract Ceased WO2006136963A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06795540A EP1898945B1 (en) 2005-06-24 2006-06-23 Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract
US11/993,264 US20100279925A1 (en) 2005-06-24 2006-06-23 Airway Administration of Site-Inactived FVIIA in Inflammatory Conditions Affecting the Respiratory Tract
DK06795540.1T DK1898945T3 (en) 2005-06-24 2006-06-23 Airway administration of site-inactivated FVIIA in inflammatory conditions affecting the airways

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
US60/693,968 2005-06-24

Publications (2)

Publication Number Publication Date
WO2006136963A2 WO2006136963A2 (en) 2006-12-28
WO2006136963A3 true WO2006136963A3 (en) 2007-07-12

Family

ID=37570814

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IB2006/002773 Ceased WO2007012976A2 (en) 2005-06-24 2006-06-23 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
PCT/IB2006/002602 Ceased WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
PCT/IB2006/002631 Ceased WO2006136963A2 (en) 2005-06-24 2006-06-23 Airway administration of site-inactivated fviia in inflammatory conditions affecting the respiratory tract

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/IB2006/002773 Ceased WO2007012976A2 (en) 2005-06-24 2006-06-23 Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
PCT/IB2006/002602 Ceased WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract

Country Status (14)

Country Link
US (3) US8088728B2 (en)
EP (3) EP1898945B1 (en)
JP (3) JP2008543926A (en)
KR (2) KR20080071116A (en)
CN (2) CN101262880A (en)
AU (2) AU2006273696B2 (en)
BR (2) BRPI0613137A2 (en)
CA (2) CA2612597C (en)
DK (3) DK1896059T3 (en)
IL (2) IL188221A0 (en)
NO (2) NO20080434L (en)
RU (2) RU2496515C2 (en)
WO (3) WO2007012976A2 (en)
ZA (2) ZA200800251B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512350A (en) * 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ Method for treating cystic fibrosis or pneumonia with bacterial infection by pulmonary administration of fosfomycin
JP6273272B2 (en) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー Treatment of inflammatory skin disorders
ES2890623T3 (en) 2014-04-16 2022-01-20 Zz Biotech Llc Use of APC analog for wound healing
DK3137102T3 (en) 2014-04-16 2021-10-11 Zz Biotech Llc APC FOR USE FOR THE TREATMENT OF ABNORMAL CUTANE FORMATION
CA3036553A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087605A2 (en) * 2001-05-02 2002-11-07 Novo Nordisk A/S Modified fvii in treatment of ards
US6497877B1 (en) * 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
WO2006026998A1 (en) * 2004-09-10 2006-03-16 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (en) * 1989-08-18 1989-08-18 Novo Nordisk As PROTEINS
SE9200541D0 (en) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab NEW USEE OF OMEGA-3-FATTY ACIDS
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
ATE321846T1 (en) * 1996-11-08 2006-04-15 Oklahoma Med Res Found USE OF A MODIFIED PROTEIN-C
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (en) * 1999-05-03 2002-09-04 Astrazeneca Ab PHARMACEUTICAL FORMULATION, KIT OF PARTS AND USE OF THE FORMULATION
JP4848092B2 (en) * 2000-02-01 2011-12-28 石原産業株式会社 Therapeutic or preventive agent for lung failure containing a diaminotrifluoromethylpyridine derivative
AU2001232736A1 (en) * 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
DE10132307A1 (en) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Pharmaceutical preparation for inhalation of antithrombin in inflammatory lung diseases and ARDS
BR0213293A (en) * 2001-10-15 2004-12-21 Chiron Corp Use of tfpi or tfpi analog in the treatment of septicemia
KR100674315B1 (en) * 2002-02-08 2007-01-24 에스케이 주식회사 Furnace Tube Cleaners and Cleaning Methods
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
ES2321297T3 (en) * 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. STABILIZED WATER COMPOSITIONS THAT INCLUDE INHIBITOR OF THE TISSULAR FACTOR VIA (IVFT) OR VARIANTE OF THE INHIBITOR OF THE TISSUE FACTOR VIA.
EP1609471A1 (en) * 2003-03-31 2005-12-28 Kyowa Hakko Kogyo Co., Ltd. Remedy and/or preventive for lung diseases
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
CA2582353A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6497877B1 (en) * 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
WO2002087605A2 (en) * 2001-05-02 2002-11-07 Novo Nordisk A/S Modified fvii in treatment of ards
WO2006026998A1 (en) * 2004-09-10 2006-03-16 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRUDHOMME J B ET AL: "Acute lung injury and acute respiratory distress syndrome: mechanisms and potential new therapies", DRUG DISCOVERY TODAY: DISEASE MECHANISMS, ELSEVIER, vol. 1, no. 1, October 2004 (2004-10-01), pages 123 - 128, XP004689271, ISSN: 1740-6765 *

Also Published As

Publication number Publication date
RU2008102655A (en) 2009-07-27
EP1906994B1 (en) 2014-04-23
EP1896059B1 (en) 2012-12-19
US20100160218A1 (en) 2010-06-24
WO2006136962A2 (en) 2006-12-28
DK1898945T3 (en) 2013-03-25
JP2013151510A (en) 2013-08-08
IL188220A0 (en) 2008-03-20
DK1906994T3 (en) 2014-07-21
NO20080434L (en) 2008-03-17
US8088728B2 (en) 2012-01-03
AU2006273696A1 (en) 2007-02-01
WO2006136962A3 (en) 2007-07-12
CA2612646C (en) 2015-11-24
WO2007012976A3 (en) 2007-07-12
CA2612597C (en) 2015-03-31
BRPI0613137A2 (en) 2010-12-21
CA2612597A1 (en) 2007-02-01
WO2007012976A2 (en) 2007-02-01
BRPI0611710A2 (en) 2011-12-20
NO20080433L (en) 2008-03-19
ZA200800255B (en) 2009-04-29
CN101262880A (en) 2008-09-10
ZA200800251B (en) 2009-04-29
HK1114567A1 (en) 2008-11-07
DK1896059T3 (en) 2013-04-08
AU2006273696B2 (en) 2012-08-30
EP1898945A2 (en) 2008-03-19
WO2006136963A2 (en) 2006-12-28
IL188221A0 (en) 2008-03-20
EP1906994A2 (en) 2008-04-09
US20100297099A1 (en) 2010-11-25
RU2008102656A (en) 2009-07-27
EP1898945B1 (en) 2012-12-19
AU2006260599A1 (en) 2006-12-28
EP1896059A2 (en) 2008-03-12
RU2496516C2 (en) 2013-10-27
KR20080071116A (en) 2008-08-01
US20100279925A1 (en) 2010-11-04
KR20080074085A (en) 2008-08-12
JP2008543925A (en) 2008-12-04
CA2612646A1 (en) 2006-12-28
RU2496515C2 (en) 2013-10-27
CN101262879B (en) 2013-04-10
JP2008543926A (en) 2008-12-04
CN101262879A (en) 2008-09-10

Similar Documents

Publication Publication Date Title
WO2006083989A3 (en) Continuous flow selective delivery of therapeutic gas
CY1111133T1 (en) EXTRAORDINARY FORMOTEROL PREPARATION
EP2746290A3 (en) Polypeptides, antibody variable domains and antagonists
WO2006105401A3 (en) Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
WO2008069972A3 (en) Systems for effecting cessation of tobacco use
WO2007091267A3 (en) Pulmonary delivery of alpha-i proteinase inhibitor
WO2009112274A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2009112273A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MX2007008379A (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs.
WO2010094720A3 (en) Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2009141321A3 (en) Tablettable chewing gums comprising nicotine and a buffering agent
WO2006033963A3 (en) Method and system of scoring sleep disordered breathing
WO2009134524A3 (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2008151235A3 (en) Compositions for delivering medicaments into the lungs, uses thereof
PH12012500826A1 (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
FI20070937A7 (en) Family swing
NO20080434L (en) Airway administration of tissue factor Road Inhibitors in inflammatory conditions affecting the respiratory tract
WO2008015695A3 (en) Inclusion complex of olopatadine and cyclodextrin
NO20073909L (en) Nebulized formulation
BRPI0515163A (en) methods for treating hemoptysis or local tracheal, bronchial or alveolar bleeding
WO2006017752A8 (en) Sulfated oligosaccharides
WO2008017065A3 (en) Gas delivery system and method
WO2007009895A3 (en) USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY
HK1115319A (en) Airway administration of activated protein c in inflammatory conditions affecting the respiratory tract
WO2006124556A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006795540

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11993264

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06795540

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006795540

Country of ref document: EP